Gene · 1723
Papers2,016
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,016
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma. | EMBO Mol Med | 2025 | 40707702 | PubTator, text mining | PubMed |
| Exploiting genetic and environmental vulnerabilities to target DHODH in CNS tumors. | Neurooncol Adv | 2025 | 40703800 | PubTator, text mining | PubMed |
| Crystallographic Structure of Human Dihydroorotate Dehydrogenase in Complex with the Natural Product Inhibitor Lapachol. | ACS Omega | 2025 | 40686985 | PubTator, text mining | PubMed |
| Direct long-read visualization reveals hidden variation in GCH1 gene copy number and precise expansion steps. | BMC Genomics | 2025 | 40676505 | PubTator, text mining | PubMed |
| Carboxylic Acid Bioisosteres Boost Nurr1 Agonist Selectivity. | J Med Chem | 2025 | 40674328 | PubTator, text mining | PubMed |
| The role and mechanism of the cGAS-STING pathway-mediated ROS in apoptosis and ferroptosis induced by manganese exposure. | Redox Biol | 2025 | 40652697 | PubTator, text mining | PubMed |
| Invasive lobular carcinoma: integrated multi-omics analysis reveals silencing of Argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance. | Cell Death Dis | 2025 | 40645971 | PubTator, text mining | PubMed |
| Targeting dihydroorotate dehydrogenase (DHODH) for host-directed therapy: Discovery of a novel alkyne-based scaffold inhibitor effective against SARS-CoV-2. | Eur J Med Chem | 2025 | 40592187 | PubTator, text mining | PubMed |
| Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors. | Br J Dermatol | 2025 | 40577595 | PubTator, text mining | PubMed |
| Synergistic interference with SARS-CoV-2 replication by molnupiravir-derived N4-hydroxycytidine and inhibitors of CTP synthetase in cell culture. | Virology | 2025 | 40561865 | PubTator, text mining | PubMed |
| Fluorescent Isostere (Fluostere) of the Carboxylate: Design of hDHODH Fluorescent Inhibitors as Proof of Concept. | J Med Chem | 2025 | 40530899 | PubTator, text mining | PubMed |
| DHODH Blockade Induces Ferroptosis in Neuroblastoma by Modulating the Mevalonate Pathway. | Mol Cell Proteomics | 2025 | 40513779 | PubTator, text mining | PubMed |
| Targeting programmed cell death with natural products: a potential therapeutic strategy for diminished ovarian reserve and fertility preservation. | Front Pharmacol | 2025 | 40510420 | PubTator, text mining | PubMed |
| A Metal-Phenolic Network Nanoresensitizer Overcoming Glioblastoma Drug Resistance through the Metabolic Adaptive Strategy and Targeting Drug-Tolerant Cells. | Nano Lett | 2025 | 40489242 | PubTator, text mining | PubMed |
| Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence. | Cureus | 2025 | 40376321 | PubTator, text mining | PubMed |
| Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001). | Pharmaceutics | 2025 | 40284407 | PubTator, text mining | PubMed |
| Genetic variants associated with physiological and biochemical indicators: A multi-centre whole-exome sequencing study of Chinese healthy participants. | Clin Transl Med | 2025 | 40205807 | PubTator, text mining | PubMed |
| Accelerating drug discovery targeting dihydroorotate dehydrogenase using machine learning and generative AI approaches. | Comput Biol Chem | 2025 | 40188690 | PubTator, text mining | PubMed |
| Targeting vulnerability in tumor therapy: Dihydroorotate dehydrogenase. | Life Sci | 2025 | 40187643 | PubTator, text mining | PubMed |
| Unsaturated fatty acid-doped liposomes deliver piperine to deactivate defensive mechanism for ferroptosis in cancer therapy. | J Control Release | 2025 | 40122242 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1723/papers?page=9